reatment failed TB patients have very limited chances of survival. Open label trial of daily oral pill of V-5 Immunitor (V5) was conducted in 48 treatment-failed TB patients on palliative support consisting of isoniazid (H) and rifampicin (R). The subjects had the following forms of TB; cavitary: disseminated: MDR-TB: DR-TB: TB/HIV at 35:13:7:4:1 ratio. After 1 month 62.5% of V5-treated patients experienced negative sputum smear conversion (P < 0.0001), comprising 11 out of 12 (91.7%) converted among those who had drug-resistant TB and TB/HIV. TB-associated inflammation was downregulated as evidenced by normalization of leukocytosis 7.4 vs. 6.7 x 109 L (P = 0.01) and decreased erythrocyte sedimentation rate 20.5 vs. 14.9 mm/h (P < 0.0001). The mean body temperature normalized from 37.25° ± 0.6° to 36.98° ± 0.4° (P = 0.0002). The average body weight gain and body mass index (BMI) increased by 0.8 ± 0.7 kg and from 18.9 to 19.6 kg/m<sup>2</sup> respectively (P < 0.0001). Two patients (4.2%) died from illicit drug- and alcohol-abuse related causes. No adverse effects or reactivation of disease due to immune intervention were seen at any time. V5 is safe and in combination with a simple two-drug regimen was highly effective as an immune adjunct to produce favorable outcome among treatment-failed and/ or drug-resistant TB patients.
Lienhardt, C., Vernon, A. and Raviglione, M.C. (2010) New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 16, 186-193. doi:10.1097/MCP.0b013e328337580c
Tiemersma, E.W., van der Werf, M.J., Borgdorff, M.W., Williams, B.G. and Nagelkerke, N.J. (2011) Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One, 6, e17601. doi:10.1371/journal.pone.0017601
Goble, M., Iseman, M.D., Madsen, L.A., Waite, D., Ackerson, L. and Horsburgh, C.R. Jr. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine, 328, 527-532. doi:10.1056/NEJM19930225328080
Churchyard, D.J. (2007) Report of the expert consultation on immunotherapeutic interventions for tuberculosis. TDR/World Health Organization, Geneva, Switzerland. http://apps.who.int/tdr/publications/tdr-research-publications/immunotherapeutic-interventions-tb/pdf/interventions-tb.pdf
Batdelger, D., Dandii, D., Jirathitikal, V. and Bourinbaiar, A.S. (2007) Open label trial of therapeutic hepatitis B vaccine V-5 Immu-nitor (V5) delivered by oral route. Letters in Drug Design and Discovery, 4, 540-544, 2007. doi:10.2174/157018007782794545
Batdelger, D., Dandii, D., Jirathitikal, V. and Bourinbaiar, A.S. (2008) Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine, 26, 2733-2737. doi:10.1016/j.vaccine.2008.03.021
Batdelger, D., Dandii, D., Dahgwahdorj, Ya., Erdenetsogt, E., Oyunbileg, J., Tsend, N., Bayarmagnai, B., Jirathitikal, V. and Bourin-baiar, A.S. (2009) Clinical experience with therapeutic vaccines designed for patients with hepatitis. Current Pharmaceutical Design, 15, 1159-1171. doi:10.2174/138161209787846793
Arjanova, O.V., Prihoda, N.D., Yurchenko, L.V., Sokolenko, N.I., Frolov, V.M., Tarakanovskaya, M.G., Jirathitikal, V. and Bourin-baiar, A.S. (2010) Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. Journal of Vaccines and Vaccination, 1, 103. doi:10.4172/2157-7560.1000103
Butov, D.A., Pashkov, Y.N., Stepanenko, A.L., Choporova, A.I., Butova, T.S., Batdelger, D., Jirathitikal, V., Bourinbaiar, A.S. and Zaitzeva, S.I. (2011) Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi- drug-resistant (MDR) TB. Journal of Immune Based Therapies and Vaccines, 9, 3. doi:10.1186/1476-8518-9-3
Arjanova, O.V., Prihoda, N.D., Yurchenko, L.V., Sokolenko, N.I., Frolov, V.M., Tarakanovskaya, M.G., Batdelger, D., Jirathitikal, V. and Bourinbaiar, A.S. (2011) Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Im-munotherapy, 3, 181-191. doi:10.2217/imt.10.96
Nuermberger, E.L., Spigelman, M.K. and Yew, W.W. (2010) Current development and future prospects in chemotherapy of tubercu-losis. Respirology, 15, 764-778. doi:10.1111/j.1440-1843.2010.01775.x
Becerra, M.C., Freeman, J., Bayona, J., Shin, S.S., Kim, J.Y., Furin, J.J., Werner, B., Sloutsky, A., Timperi, R., Wilson, M.E., Pagano, M. and Farmer, P.E. (2000) Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Diseases, 4, 108-114. PMid:10694087
Johnston, J.C., Shahidi, N.C., Sadatsafavi, M. and Fitzgerald, J.M. (2009) Treatment outcomes of multidrug- resistant tuberculosis: a systematic review and meta- analysis. PLoS One, 4, e6914. doi:10.1371/journal.pone.0006914
Faustini, A., Hall, A.J. and Perucci, C.A. (2005) Tuber- culosis treatment outcomes in Europe: a systematic re- view. European Res-piratory Journal, 26, 503-510. doi:10.1183/09031936.05.00103504
Khan, A., Sterling, T.R., Reves, R., Vernon, A. and Horsburgh, C.R. (2006) Lack of weight gain and relapse risk in a large tuberculo-sis treatment trial. American Journal of Respiratory and Critical Care Medicine, 174, 344-348. doi:10.1164/rccm.200511-1834OC
Bernabe-Ortiz, A., Carcamo, C.P., Sanchez, J.F. and Rios, J. (2011) Weight variation over time and its association with tuberculosis treatment outcome: a longitudinal analysis. PLoS One, 6, e18474. doi:10.1371/journal.pone.0018474
Zafran, N., Heldal, E., Pavlovic, S., Vuckovic, D. and Boe, J. (1994) Why do our patients die of active tuberculosis in the era of ef-fective therapy? Tuberculosis and Lung Disease, 75, 329-333. doi:10.1016/0962-8479(94)90077-9
Franke, M.F., Appleton, S.C., Bayona, J., Arteaga, F., Palacios, E., Llaro, K., Shin, S.S., Becerra, M.C., Murray, M.B. and Mitnick, C.D. (2008) Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clinical Infectious Diseases, 46, 1844-1851. doi:10.1086/588292
Akintunde, E.O., Shokunbi, W.A. and Adekunle, C.O. (1995) Leucocyte count, platelet count and erythrocyte sedimentation rate in pulmonary tuberculosis. African Journal of Medicine and Medical Science, 24, 131-134. PMid:8669390
Barnes, P.F. (2003) Immunotherapy for tuberculosis: wave of the future or tilting at windmills? American Journal of Respiratory and Critical Care Medicine, 168, 142-143. doi:10.1164/rccm.2305001
Churchyard, GJ, Kaplan, G, Fallows, D, Wallis, RS, Onyebujoh, P. and Rook, GA. (2009) Advances in immunotherapy for tuberculo-sis treatment. Clinical Chest Medicine, 30, 769-782. doi:10.1016/j.ccm.2009.08.009
Dheda, K., Schwander, S.K., Zhu, B., van Zyl-Smit, R.N. and Zhang, Y. (2010) The immunology of tuberculosis: from bench to bed-side. Respirology, 15, 433-450. doi:10.1111/j.1440-1843.2010.01739.x
Grange, J.M., Brunet, L.R. and Rieder, H.L. (2011) Immune protection against tuberculosis-when is immunotherapy preferable to vaccination? Tuberculosis, 91, 179-185. doi:10.1016/j.tube.2010.12.004
Silin, D.S., Lyubomska, O.V., Ershov, F.I., Frolov, V.M. and Kutsyna, G.A. (2009) Immunomodulators with interferon inducing properties. Current Pharmaceutical Design, 15, 1238-1247. doi:10.2174/138161209787846847
Arjanova, O.V., Prihoda, N.D., Sokolenko, N.I., Yurchenko, L.V., Vihrova, L.A., Pylypchuk, V.S., Frolov, V.M. and Kutsyna, G.A. (2009) Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients. Journal of Antivirals and Antiretrovirals, 1, 86-88. doi:10.4172/jaa.1000013
Stanford, J., Stanford, C. and Grange, J. (2004) Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Fron-tiers in Bioscience, 9, 1701-1719. doi:10.2741/1292